(PRESS RELEASE) HERZLIYA, ISRAEL — Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, announced the appointment of Teresa (Tes) Ignacio, M.D. as vice president, Medical Affairs. Dr. Ignacio, a fellowship-trained Ophthalmologist, brings over a decade of experience in research and development, clinical and medical affairs.
“I am thrilled to join Orasis Pharmaceuticals at such a pivotal time as we advance CSF-1 toward commercialization,” said Dr. Ignacio. “It’s a privilege to be part of this team as we pioneer a preservative-free presbyopia solution designed with the patient in mind.”
Paul Smith, president and chief operating officer of Orasis, added, “We are pleased to have Tes join the Orasis team at such a critical time with the completion of Phase 3 NEAR-1 and NEAR-2 clinical trials and pre-commercialization efforts underway. We look forward to leveraging her expertise as we complete the analysis of our Phase 3 studies and begin sharing those results with the scientific community.”
Dr. Ignacio brings extensive experience in providing scientific and medical affairs strategy for the ophthalmic market, from early development stage to product life cycle management. She has also led several product launches across surgical device, pharmaceutical and over-the-counter markets. Dr. Ignacio trained at UC Irvine as a Cornea and Refractive Research Fellow and completed her ophthalmology residency at Makati Medical Center in the Philippines.
